| Dr Julian K Wu, MD | |
|
750 Washington St, Boston, MA 02111-1526 | |
| (508) 636-4500 | |
| Not Available |
| Full Name | Dr Julian K Wu |
|---|---|
| Gender | Male |
| Speciality | Neurosurgery |
| Experience | 43 Years |
| Location | 750 Washington St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205887031 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207T00000X | Neurological Surgery | 58178 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Tufts Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New England Medical Center Group Practice Inc | 4789647405 | 25 |
News Archive
PLx Pharma Inc, a Houston-based pharmaceutical company developing a medical discovery made at The University of Texas Health Science Center at Houston (UTHealth) Medical School, has been awarded $565,449 for the first year of a potential two-year $1,118,398 grant to conduct research designed to enhance a treatment for premature babies with a common congenital heart defect.
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
More than half the world's population is at risk from diseases such as malaria, dengue, leishmaniasis, Lyme disease, schistosomiasis, and yellow fever, carried by mosquitoes, flies, ticks, water snails and other vectors. Every year, more than one billion people are infected and more than one million die from vector-borne diseases.
A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other institutions.
› Verified 5 days ago
| Entity Name | New England Medical Center Group Practice Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487601787 PECOS PAC ID: 4789647405 Enrollment ID: O20041104000424 |
News Archive
PLx Pharma Inc, a Houston-based pharmaceutical company developing a medical discovery made at The University of Texas Health Science Center at Houston (UTHealth) Medical School, has been awarded $565,449 for the first year of a potential two-year $1,118,398 grant to conduct research designed to enhance a treatment for premature babies with a common congenital heart defect.
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
More than half the world's population is at risk from diseases such as malaria, dengue, leishmaniasis, Lyme disease, schistosomiasis, and yellow fever, carried by mosquitoes, flies, ticks, water snails and other vectors. Every year, more than one billion people are infected and more than one million die from vector-borne diseases.
A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other institutions.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Julian K Wu, MD 6 Bennett Rd, Wayland, MA 01778-2704 Ph: (508) 636-4500 | Dr Julian K Wu, MD 750 Washington St, Boston, MA 02111-1526 Ph: (508) 636-4500 |
News Archive
PLx Pharma Inc, a Houston-based pharmaceutical company developing a medical discovery made at The University of Texas Health Science Center at Houston (UTHealth) Medical School, has been awarded $565,449 for the first year of a potential two-year $1,118,398 grant to conduct research designed to enhance a treatment for premature babies with a common congenital heart defect.
Elan Corporation, plc today announced that findings from a Phase II study which suggested bapineuzumab reduced amyloid-beta deposits in the brains of Alzheimer's disease patients as measured using a neuroimaging technique known as [11C]PiB PET, were published in the February 28, 2010 online edition of Lancet Neurology. Bapineuzumab is a compound under development by Pfizer and Janssen Alzheimer Immunotherapy, a Johnson & Johnson subsidiary in which Elan holds a minority equity interest.
More than half the world's population is at risk from diseases such as malaria, dengue, leishmaniasis, Lyme disease, schistosomiasis, and yellow fever, carried by mosquitoes, flies, ticks, water snails and other vectors. Every year, more than one billion people are infected and more than one million die from vector-borne diseases.
A group of small molecules called EETs - currently under scrutiny as possible treatment targets for a host of cardiovascular diseases - may also drive the growth and spread of cancer, according to researchers at the Dana-Farber/Children's Hospital Cancer Center (DF/CHCC) and other institutions.
› Verified 5 days ago
Wenya Linda Bi, Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 203-645-9485 Fax: 617-732-5500 | |
Dr. Justin Lee Massengale, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 725 Albany St, Shapiro 7, Suite C, Boston, MA 02118 Phone: 617-638-8992 Fax: 617-638-8979 | |
Scellig S Stone, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-1484 | |
Dr. Mohammad Ali Aziz-sultan, M.D. Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 75 Francis St, Boston, MA 02115 Phone: 617-732-6600 | |
Hormuzdiyar Henry Dasenbrock, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 725 Albany Street, Shapiro 7, Suite C, Boston, MA 02118 Phone: 617-638-8992 | |
Ganesh M Shankar, MD, PHD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St., Massachusetts General Hospital, Boston, MA 02114 Phone: 617-726-5143 | |
Dr. Justin M Brown, MD Neurological Surgery Medicare: Accepting Medicare Assignments Practice Location: 55 Fruit St # 745, Boston, MA 02114 Phone: 617-726-8582 Fax: 858-822-4715 |